DE69836229D1 - Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren - Google Patents

Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren

Info

Publication number
DE69836229D1
DE69836229D1 DE69836229T DE69836229T DE69836229D1 DE 69836229 D1 DE69836229 D1 DE 69836229D1 DE 69836229 T DE69836229 T DE 69836229T DE 69836229 T DE69836229 T DE 69836229T DE 69836229 D1 DE69836229 D1 DE 69836229D1
Authority
DE
Germany
Prior art keywords
calcium channels
nucleic acid
compositions
activated calcium
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69836229T
Other languages
English (en)
Other versions
DE69836229T2 (de
Inventor
Mark Williams
Kenneth Stauderman
Michael Harpold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/984,709 external-priority patent/US6528630B1/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69836229D1 publication Critical patent/DE69836229D1/de
Publication of DE69836229T2 publication Critical patent/DE69836229T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69836229T 1997-12-03 1998-12-03 Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren Expired - Fee Related DE69836229T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/984,709 US6528630B1 (en) 1997-12-03 1997-12-03 Calcium channel compositions and methods
US984709 1997-12-03
US18893298A 1998-11-10 1998-11-10
US188932 1998-11-10
PCT/US1998/025671 WO1999028342A2 (en) 1997-12-03 1998-12-03 Low-voltage activated calcium channel compositions and methods

Publications (2)

Publication Number Publication Date
DE69836229D1 true DE69836229D1 (de) 2006-11-30
DE69836229T2 DE69836229T2 (de) 2007-08-23

Family

ID=26884607

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836229T Expired - Fee Related DE69836229T2 (de) 1997-12-03 1998-12-03 Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren

Country Status (8)

Country Link
EP (1) EP1042468B1 (de)
JP (1) JP2001525161A (de)
AT (1) ATE342973T1 (de)
AU (1) AU760309B2 (de)
CA (1) CA2312195A1 (de)
DE (1) DE69836229T2 (de)
ES (1) ES2274588T3 (de)
WO (1) WO1999028342A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297504B1 (en) 1997-02-28 2007-11-20 Neuromed Pharmaceuticals Ltd. Methods for identifying agonists and antagonists of human T-type calcium channels
EP1190053A2 (de) * 1999-07-02 2002-03-27 Neuromed Technologies, Inc. Säugetier-kaliumkanäle und verwandte proben, zelllinien und verfahren
JP2003512602A (ja) * 1999-09-16 2003-04-02 ワーナー−ランバート・カンパニー α２δ−１サブユニット結合リガンドのスクリーニング方法
US6358706B1 (en) 1999-10-26 2002-03-19 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding human alpha1G-C T-Type calcium channel
WO2001083752A2 (en) * 2000-04-29 2001-11-08 Millennium Pharmaceuticals, Inc. 23949 and 32391, human ion channels and uses thereof
AU2001292258A1 (en) * 2000-10-02 2002-04-15 Nippon Chemiphar Co., Ltd. Remedies for hepatic diseases containing calcium channel antagonist as the active ingredient
UA79927C2 (en) * 2000-12-05 2007-08-10 Serono Genetics Inst Sa Polynucleotide, coding a polypeptide of potential-depending portal ionic human channel (canion), polypeptyde, antibody, method for identification of candidate modulator of canion-polypeptyde, method for treatment of bipolar disorder or schizophrenia and use of an antibody for production of drugs for treatment of schizophrenia or bipolar disorder
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
WO2003039449A2 (en) * 2001-11-07 2003-05-15 Medical Research Council Modulation of dopaminergic neurons
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
US7084116B2 (en) 2003-03-10 2006-08-01 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators
US7125848B2 (en) 2003-06-13 2006-10-24 Dynogen Pharmaceuticals, Inc. Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators
US20070178462A1 (en) * 2004-02-18 2007-08-02 Uebele Victor N Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US20080003633A1 (en) * 2004-12-13 2008-01-03 Heesup Shin Methods for Relieving Neuropathic Pain by Modulating Alpha1G T-Type Calcium Channels and Mice Lacking Alpha 1G T-Type Calcium Channels
CA2700974A1 (en) 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
EP2209373B1 (de) 2007-10-04 2012-05-23 Merck Sharp & Dohme Corp. N-substituierte oxindolinderivate als kalziumkanalblocker
JP5723600B2 (ja) 2008-02-29 2015-05-27 ブイエム ディスカバリー インコーポレイテッド 疼痛症候群および他の障害の治療法
WO2011053542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
JP6017964B2 (ja) 2010-03-01 2016-11-02 ティーエーユー・セラピューティクス・エルエルシー 癌診断および撮像
WO2013148640A1 (en) 2012-03-29 2013-10-03 Merck Sharp & Dohme Corp. Imidazolyl methyl piperidine t-type calcium channel antagonists
EP3548888B1 (de) 2016-12-02 2023-04-05 Sophion Bioscience A/S Dichtungsverstärker
WO2018100206A1 (en) * 2016-12-02 2018-06-07 Sophion Bioscience A/S Seal enhancer
CN115979923B (zh) * 2023-03-20 2023-06-27 中国有色金属工业昆明勘察设计研究院有限公司 一种尾矿库渗透破坏模拟试验装置及试验方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113203C (en) * 1991-08-15 2001-01-02 Michael Miller Harpold Human calcium channel compositions and methods
ATE196651T1 (de) * 1993-07-30 2000-10-15 Elan Pharm Inc Für die alpha-1e untereinheit des menschlichen kalziumkanals kodierende dna

Also Published As

Publication number Publication date
ES2274588T3 (es) 2007-05-16
AU1802699A (en) 1999-06-16
EP1042468B1 (de) 2006-10-18
EP1042468A2 (de) 2000-10-11
WO1999028342A2 (en) 1999-06-10
CA2312195A1 (en) 1999-06-10
WO1999028342A3 (en) 1999-08-26
DE69836229T2 (de) 2007-08-23
JP2001525161A (ja) 2001-12-11
AU760309B2 (en) 2003-05-15
ATE342973T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
DE69836229D1 (de) Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren
DE68926713T2 (de) Calciumkanal-zusammensetzungen und verfahren
GB9503692D0 (en) Human calcium channel compositions and methods of using them
ES2147184T3 (es) Composiciones de canales calcicos humanos y procedimientos.
WO2000005366A3 (en) Xiap ires and uses thereof
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
ES2193145T3 (es) Proteinas procoagulants quimericas.
ATE268782T1 (de) Zusammensetzungen zur wundheilung
ATE405586T1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
CY1111278T1 (el) Συστημα ασφαλειας
EA200000239A1 (ru) Стимуляторы секреции гормона роста
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
WO1995034651A3 (en) Corticotropin-releasing factor2 receptors
DE69905273D1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
DE59900730D1 (de) Korrosionsinhibitoren enthaltender Injektionszement
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
DE69104357T2 (de) Klonierungs- und/oder expressionsvektoren, verfahren zur ihrer herstellung und verwendung.
ATE389014T1 (de) Phosphorylierte glyoxalase i und deren verwendung
EP0860501A3 (de) Corticotropin freisetzende Rezeptoren des Faktor 2
SE8401783D0 (sv) Anordning vid stapling av seckar

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee